Singapore, April 21 -- US-based 5 Horizons Ventures and Australia's Biointelect have announced a strategic partnership and investment alliance designed to help promising biotech and medtech ventures navigate one of the most challenging phases of development.

The partnership aims to accelerate progress through early-stage clinical trials, where many companies face both financial and operational hurdles.

By combining 5 Horizons Ventures' global investment network with Biointelect's established strengths in clinical development strategy, regulatory navigation, pricing access and evidence generation, the partnership offers a more integrated pathway from concept to clinical validation.

It is structured to provide hands-on support and capita...